Skip to main navigation

Menu

Skip to content

Investors

Alnylam

E-mail Alerts

Download Center

Print

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

FinancialMenu

Fundamentals
Financial Information
Quarterly Results
Key Ratios
Annual Reports

Here you will find a summary of Alnylam Pharmaceuticals, Inc.'s latest financial information.

Show all

Latest Earnings Release and 10-Q

Third Quarter Financial Results
Form 10-Q

Show all

Latest Annual Report and 10-K

2016 Annual Report
Form 10-K

Show all

Latest Proxy Statement

Latest Proxy Statement

Share Related Items

Market Capitalization (Mil)	$9,035.45
Shares Outstanding (Mil)	106.44
Shares Outstanding, Average (FY) (Mil)	100.59
Float (Mil)	94.96

Copyright Thomson Reuters Corporation

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Search

Recent Press Releases

View all releases

Apr 15,2019

Summary Toggle Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
Apr 12,2019

Summary Toggle Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
Apr 08,2019

Summary Toggle Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of Copyright NASDAQ. Minimum 15 minutes delay

twitter
linkedin
youtube
rss

Copyright © 2019 Alnylam Pharmaceuticals, Inc. --- All Rights Reserved --- Glossary | Media Kit | Legal | Privacy Policy | Site Map